The Prix Galien USA Committees honored excellence and innovation in life sciences during the Prix Galien USA Forum and 17h annual Prix Galien Awards Gala last week at the American Museum of Natural History in New York City.

The USA Committees, composed of 20 committee members, 12 subcommittee members and 20 advisory board members, represented renowned leaders from the biomedical industry and academia. With three Nobel Laureates, these groups honored this year’s award winners in the following categories: “Best Biotechnology Product,” “Best Pharmaceutical Product,” “Best Product for Rare/Orphan Diseases,” “Best Medical Technology,” “Best Digital Health Solution,” “Incubators, Accelerators and Equity” and “Best Startup.”

“We are delighted to extend the Prix Galien legacy to another distinguished cohort of winners who have demonstrated the unparalleled skill, innovation, and dedication required across the life sciences industry,” says Bruno Cohen, Chairman of The Galien Foundation. “Our Awards Committee, Prix Galien Alumni, and all members of The Galien Foundation extend our gratitude to each winner and nominee, and we look forward to witnessing their impact on the future of global healthcare.”

Novo Nordisk’s Ozempic awarded

In the category Best pharmaceutical product, the winners were Novo Nordisk’s Ozempic (semaglutide) and Eli Lilly and Company’s Mounjaro (tirzepatide) Injection, for their paradigm-shifting diabetes and anti-obesity drugs.

Read more: From theory to therapy: Anti-obesity drugs

Best Biotechnology Product

The Best Biotechnology Product award winner was Bristol Myers Squibb for Camzyos (mavacamten), used in adults to treat obstructive hypertrophic cardiomyopathy.

Best Product for Rare/Orphan Diseases

Best Product for Rare/Orphan Diseases was Boehringer Ingelheim’s Spevigo (spesolimab), the first and only FDA approved medical treatment for adult patients with Generalized Pustular Psoriasis (GPP) flares, and CSL/uniQure’s HEMGENIX, the first and only FDA-approved gene therapy for hemophilia B.

Read more: First gene therapy for hemophilia B approved in the EU

Best Medical Technology

The Best Medical Technology award honored Guardant Health’s Guardant360 CDx, the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors that delivers results in as soon as 7 days.

Best Digital Health Solution and Incubators, Accelerators and Equity

The Best Digital Health Solution was Medable’s Medable Decentralized Clinical Trials (DCT) Platform and the winner of the category Incubators, Accelerators and Equity was Villgro Africa’s Incubating Healthcare Startups in Africa.

Best Startup

The Best Startups were GrayMatters Health (Israel), Tessera Therapeutics (USA), and Volta Medical (France).

The Prix Galien Awards

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Its vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.

The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa. The Prix Galien was created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

Featured photo of (r) Stephen L. Gough, Novo Nordisk Ambassador: Galien Foundation